NeuroEM Therapeutics
PrivateLast Round
Series A
Jun 13, 2025
Est. Valuation
$14.3M
Total Funding Raised
$3.65M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NeuroEM Therapeutics operates in Healthcare & Life Sciences and is based in Tampa, Florida. Its latest recorded funding round was a Grant round in June 2007.
NeuroEM Therapeutics is a therapeutic devices company developing a non-invasive, wearable head device that uses transcranial electromagnetic treatment to combat cognitive impairment caused by neurodegenerative conditions like Alzheimer's disease.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2C
Customer Profile
Hardware Sales, Hardware + Subscription, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeuroEM Therapeutics Comparables
Compare NeuroEM Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cognito Therapeutics | 82% | |
| Vielight Inc. | 81% | |
| Grey Matter Neurosciences | 81% |
For institutional investors. Book with your work email.
NeuroEM Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 13, 2025 | ||||
| Grant | Jun 1, 2007 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NeuroEM Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Rainwater Charitable Foundation | VC Round |
| Glass Foundation, Inc. | VC Round |
| NIH RADx | Grant |
| Founders Fund | Early Funding |
| Angel Investor Forum | Seed |
| Bluelake Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 160% MoM, reaching 7.1K.
- Nov 6, 2025
Monthly visitors increased 48% MoM.
For institutional investors. Book with your work email.
NeuroEM Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeuroEM Therapeutics's valuation, stock price, and market status.
Is NeuroEM Therapeutics a public or private company?
NeuroEM Therapeutics is a private company.
What is the current stock price of NeuroEM Therapeutics?
NeuroEM Therapeutics is a private company, so its shares have no public market price. Caplight tracks NeuroEM Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeuroEM Therapeutics worth (valuation)?
NeuroEM Therapeutics's valuation is estimated at $14.3M based on funding round data.
Can I buy NeuroEM Therapeutics stock?
NeuroEM Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeuroEM Therapeutics's last funding round?
NeuroEM Therapeutics's most recent funding round was Series A on June 13, 2025.
Who are the main investors in NeuroEM Therapeutics?
Key investors in NeuroEM Therapeutics include Bluelake Ventures.
Will NeuroEM Therapeutics IPO soon?
No public IPO plans have been announced for NeuroEM Therapeutics.
How can I track NeuroEM Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NeuroEM Therapeutics's shares on secondary markets.